Ulf Teichgräber (Jena, Germany), talks to Vascular News at EuroPCR 2019 about the EFFPAC trial which compared the luminor (iVascular) drug-coated balloon (DCB) with plain old balloon angioplasty (POBA).
Teichgräber outlines the 24-month results from the trial specifically the secondary endpoints which included patency rates, freedom from target lesion revascularisation (TLR) and binary restenosis. According to Teichgräber, “we were able to maintain the great results from the 12-months to the 24-months”.
The freedom from TLR rate was 97% and the patency rate 90%. Meanwhile binary restenosis was 20% in comparison to 47% in the POBA group – results which Teichgräber describes as “astonishing” and which show that the efficacy of the product is “very high”.
Teichgräber also discusses quality of life and all-cause mortality findings which showed that there “was no increased risk” of mortality with the product. He also notes why the luminor DCB is unique which he believes is “down to the coating technology”.
This video is sponsored by iVascular.